Key Points. LAG3 is commonly found on malignant B cells in DLBCL, which may have implications for current clinical studies using anti-LAG3 compounds.LAG3 is fo
Key Points. VEN in combination with HMAs is highly effective for AML with mutant NPM1 (NPM1+).VEN with HMA therapy could be considered a mutation-targeted trea
Beutler and West have made a significant contribution in their comparison of hemoglobin levels in African-American patients with those of white patients from an
Chimeric antigen receptor (CAR) T cells expressing B-cell maturation antigen (BCMA) can target and kill multiple myeloma (MM). BCMA was chosen as a target for M
Cytokine release syndrome (CRS) is among the most representative toxicities of chimeric antigen receptor T (CART) cell therapies against non-Hodgkin's lymphoma
Key Points. uhCG is a readily available and promising supportive therapy for life-threatening aGVHD.uhCG also contains EGF, which could aid in the repair of da
Key Points. We report the first case of coronavirus disease 2019 (COVID-19) in a multiple myeloma patient successfully treated with tocilizumab.Although tocili
In this issue of Blood, van Zeventer and her colleagues in The Netherlands report mutational profiling in 676 anemic patients ≥60 years old and a group of age-m
In this issue of Blood, Mahévas et al demonstrate that an immunomodulatory drug or a proteasome inhibitor partnered with dexamethasone can lead to a clinically
In this issue of Blood, Ghannam and colleagues report on the development of myeloid malignancy in 3 individuals with homozygous sickle cell disease (SCD).1 This